AMYLIN PHARMACEUTICALS INC
10-Q, EX-27, 2000-11-14
PHARMACEUTICAL PREPARATIONS
Previous: AMYLIN PHARMACEUTICALS INC, 10-Q, 2000-11-14
Next: SPATIALIGHT INC, 10QSB, 2000-11-14



<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONSOLIDATED BALANCE SHEET AND THE CONSOLIDATED STATEMENT OF OPERATIONS.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                      15,283,000
<SECURITIES>                                78,206,000
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                            95,973,000
<PP&E>                                       3,736,000
<DEPRECIATION>                               1,976,000
<TOTAL-ASSETS>                             100,662,000
<CURRENT-LIABILITIES>                        6,292,000
<BONDS>                                              0
                                0
                                          0
<COMMON>                                        63,000
<OTHER-SE>                                  43,566,000
<TOTAL-LIABILITY-AND-EQUITY>               100,662,000
<SALES>                                              0
<TOTAL-REVENUES>                                     0
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                            30,647,000
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                           4,511,000
<INCOME-PRETAX>                            (30,198,000)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (30,198,000)
<EPS-BASIC>                                    (0.49)
<EPS-DILUTED>                                    (0.49)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission